174 related articles for article (PubMed ID: 15206726)
1. 3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease?
Guidetti P; Schwarcz R
Adv Exp Med Biol; 2003; 527():137-45. PubMed ID: 15206726
[TBL] [Abstract][Full Text] [Related]
2. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease.
Guidetti P; Luthi-Carter RE; Augood SJ; Schwarcz R
Neurobiol Dis; 2004 Dec; 17(3):455-61. PubMed ID: 15571981
[TBL] [Abstract][Full Text] [Related]
3. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum.
Guidetti P; Schwarcz R
Eur J Neurosci; 1999 Nov; 11(11):3857-63. PubMed ID: 10583474
[TBL] [Abstract][Full Text] [Related]
4. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice.
Guidetti P; Bates GP; Graham RK; Hayden MR; Leavitt BR; MacDonald ME; Slow EJ; Wheeler VC; Woodman B; Schwarcz R
Neurobiol Dis; 2006 Jul; 23(1):190-7. PubMed ID: 16697652
[TBL] [Abstract][Full Text] [Related]
5. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
Sapko MT; Guidetti P; Yu P; Tagle DA; Pellicciari R; Schwarcz R
Exp Neurol; 2006 Jan; 197(1):31-40. PubMed ID: 16099455
[TBL] [Abstract][Full Text] [Related]
6. Early kynurenergic impairment in Huntington's disease and in a transgenic animal model.
Guidetti P; Reddy PH; Tagle DA; Schwarcz R
Neurosci Lett; 2000 Apr; 283(3):233-5. PubMed ID: 10754231
[TBL] [Abstract][Full Text] [Related]
7. Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease.
Thevandavakkam MA; Schwarcz R; Muchowski PJ; Giorgini F
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):791-800. PubMed ID: 20942784
[TBL] [Abstract][Full Text] [Related]
8. Acute and chronic changes in kynurenate formation following an intrastriatal quinolinate injection in rats.
Ceresoli-Borroni G; Guidetti P; Schwarcz R
J Neural Transm (Vienna); 1999; 106(3-4):229-42. PubMed ID: 10392532
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of [5-(3)H]kynurenine in the developing rat brain in vivo: effect of intrastriatal ibotenate injections.
Ceresoli G; Guidetti P; Schwarcz R
Brain Res Dev Brain Res; 1997 May; 100(1):73-81. PubMed ID: 9174248
[TBL] [Abstract][Full Text] [Related]
10. Drosophila eye color mutants as therapeutic tools for Huntington disease.
Green EW; Campesan S; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
Fly (Austin); 2012; 6(2):117-20. PubMed ID: 22634544
[TBL] [Abstract][Full Text] [Related]
11. Kynurenergic manipulations influence excitatory synaptic function and excitotoxic vulnerability in the rat hippocampus in vivo.
Wu HQ; Guidetti P; Goodman JH; Varasi M; Ceresoli-Borroni G; Speciale C; Scharfman HE; Schwarcz R
Neuroscience; 2000; 97(2):243-51. PubMed ID: 10799756
[TBL] [Abstract][Full Text] [Related]
12. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K
Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558
[TBL] [Abstract][Full Text] [Related]
13. Early modulation of the transcription factor Nrf2 in rodent striatal slices by quinolinic acid, a toxic metabolite of the kynurenine pathway.
Colín-González AL; Luna-López A; Königsberg M; Ali SF; Pedraza-Chaverrí J; Santamaría A
Neuroscience; 2014 Feb; 260():130-9. PubMed ID: 24361737
[TBL] [Abstract][Full Text] [Related]
14. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
15. The Janus faces of 3-hydroxykynurenine: dual redox modulatory activity and lack of neurotoxicity in the rat striatum.
Colín-González AL; Maya-López M; Pedraza-Chaverrí J; Ali SF; Chavarría A; Santamaría A
Brain Res; 2014 Nov; 1589():1-14. PubMed ID: 25251594
[TBL] [Abstract][Full Text] [Related]
16. In situ produced 7-chlorokynurenate provides protection against quinolinate- and malonate-induced neurotoxicity in the rat striatum.
Guidetti P; Wu HQ; Schwarcz R
Exp Neurol; 2000 May; 163(1):123-30. PubMed ID: 10785450
[TBL] [Abstract][Full Text] [Related]
17. Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications.
Ceresoli-Borroni G; Guidetti P; Amori L; Pellicciari R; Schwarcz R
J Neurosci Res; 2007 Mar; 85(4):845-54. PubMed ID: 17279543
[TBL] [Abstract][Full Text] [Related]
18. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease.
Graham RK; Pouladi MA; Joshi P; Lu G; Deng Y; Wu NP; Figueroa BE; Metzler M; André VM; Slow EJ; Raymond L; Friedlander R; Levine MS; Leavitt BR; Hayden MR
J Neurosci; 2009 Feb; 29(7):2193-204. PubMed ID: 19228972
[TBL] [Abstract][Full Text] [Related]
19. 3-Hydroxykynurenine toxicity on the rat striatum in vivo.
Nakagami Y; Saito H; Katsuki H
Jpn J Pharmacol; 1996 Jun; 71(2):183-6. PubMed ID: 8835646
[TBL] [Abstract][Full Text] [Related]
20. Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum.
Amori L; Wu HQ; Marinozzi M; Pellicciari R; Guidetti P; Schwarcz R
Neuroscience; 2009 Mar; 159(1):196-203. PubMed ID: 19138730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
